Syngen Biotech Co., Ltd.(TW:8279)
NT$81.70+-0.10 (+1.74%)
TW:8279
Syngen Biotech Co., Ltd. financials statements
NT$81.70
At close:+-0.10 (+1.74%)
Syngen Biotech Co., Ltd. (8279) Financial Statements
Syngen Biotech Co., Ltd. Financial Overview
Syngen Biotech Co., Ltd.'s market cap is currently NT$2.21B. The company's EPS TTM is NT$7.57; its P/E ratio is 10.79; and it has a dividend yield of 6.12%. Syngen Biotech Co., Ltd. has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | NT$ 2.14B | NT$ 2.01B | NT$ 1.84B | NT$ 1.93B | NT$ 1.47B |
| Gross Profit | NT$ 723.59M | NT$ 723.94M | NT$ 643.92M | NT$ 688.15M | NT$ 528.34M |
| Operating Income | NT$ 326.98M | NT$ 303.30M | NT$ 294.28M | NT$ 419.31M | NT$ 299.03M |
| EBITDA | NT$ 448.31M | NT$ 423.57M | NT$ 442.14M | NT$ 448.88M | NT$ 380.42M |
| Net Income | NT$ 271.59M | NT$ 240.21M | NT$ 274.83M | NT$ 321.24M | NT$ 237.77M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | NT$ 275.46M | NT$ 341.93M | NT$ 366.89M | NT$ 246.05M | NT$ 314.80M |
| Total Assets | NT$ 3.05B | NT$ 3.08B | NT$ 3.11B | NT$ 3.07B | NT$ 2.42B |
| Total Debt | NT$ 315.59M | NT$ 544.80M | NT$ 681.76M | NT$ 786.53M | NT$ 236.08M |
| Net Debt | NT$ 40.13M | NT$ 202.87M | NT$ 314.87M | NT$ 540.47M | NT$ -78.72M |
| Total Liabilities | NT$ 674.89M | NT$ 848.52M | NT$ 974.63M | NT$ 1.08B | NT$ 644.16M |
| Stockholders' Equity | NT$ 2.37B | NT$ 2.24B | NT$ 2.13B | NT$ 1.99B | NT$ 1.77B |
| Cash Flow | |||||
| Free Cash Flow | NT$ 243.07M | NT$ 283.70M | NT$ 321.33M | NT$ -307.23M | NT$ 274.83M |
| Operating Cash Flow | NT$ 319.48M | NT$ 348.04M | NT$ 415.13M | NT$ 277.48M | NT$ 336.50M |
| Investing Cash Flow | NT$ -76.83M | NT$ -84.53M | NT$ -93.68M | NT$ -585.05M | NT$ -336.07M |
| Financing Cash Flow | NT$ -309.47M | NT$ -289.09M | NT$ -200.54M | NT$ 238.75M | NT$ -108.88M |
Currency in TWD
